Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

Delaware State Police have arrested 53-year-old James Thorpe of Elkton, Maryland for 9th offense felony DUI yesterday. On October 22, 2024, at approximately 4:14 p.m., a trooper on patrol saw […] The ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

The campaign “caused Americans to lose trust in the public health system,” House Energy and Commerce Committee Chair Cathy ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

Researchers evaluated protection conferred by a single COVID-19 mRNA vaccine dose vs a 2-dose series in the setting of high preexisting SARS-CoV-2 immunity.